Fred R. Hirsch

Prof. Fred R. Hirsch


Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2021 in Nature Reviews Clinical Oncology
Verified
Journal Article
Closed access
PDF file
DDDeborah Blythe Doroshow
Deborah Blythe Doroshow
SBSheena Bhalla
Sheena Bhalla
MBMary Beth Beasley
Mary Beth Beasley
LSLynette M. Sholl
Lynette M. Sholl
KKKeith M. Kerr
Keith M. Kerr
FHFred R. Hirsch
Fred R. Hirsch

6 August 2024 in The Lancet
Verified
Journal Article
Closed access
MMMay-Lucie Meyer
May-Lucie Meyer
BFBailey G Fitzgerald
Bailey G Fitzgerald
LPLuis Paz-Ares
Luis Paz-Ares
FCFederico Cappuzzo
Federico Cappuzzo
PJPasi A Jänne
Pasi A Jänne
FHFred R. Hirsch
Fred R. Hirsch

1 May 2021 in The Journal of Molecular Diagnostics
Verified
Journal Article
Closed access
RVRajwanth Veluswamy
Rajwanth Veluswamy
PMPhilip C. Mack
Philip C. Mack
JHJane Houldsworth
Jane Houldsworth
EEEhab Elkhouly
Ehab Elkhouly
FHFred R. Hirsch
Fred R. Hirsch

6 January 2025 in Nature Reviews Clinical Oncology
Verified
Journal Article
Closed access
PDF file
YWYibei Wang
Yibei Wang
MSMohammed Safi
Mohammed Safi
FHFred R. Hirsch
Fred R. Hirsch
SLShun Lu
Shun Lu
SPSolange Peters
Solange Peters
JZJianjun Zhang
Jianjun Zhang

15 October 2024 in Annals of Oncology
Verified
Journal Article
Closed access
MMM.-L. Meyer
M.-L. Meyer
SPS. Peters
S. Peters
TMT.S. Mok
T.S. Mok
SLS. Lam
S. Lam
PYP.-C. Yang
P.-C. Yang
FHFred R. Hirsch
Fred R. Hirsch

24 February 2024 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
ASAnna Solta
Anna Solta
BEBüsra Ernhofer
Büsra Ernhofer
KBKristiina Boettiger
Kristiina Boettiger
ZMZsolt Megyesfalvi
Zsolt Megyesfalvi
SHSimon Heeke
Simon Heeke
ÁGÁron Kristof Ghimessy
Áron Kristof Ghimessy
Current treatment guidelines refer to small cell lung cancer (SCLC), one of the deadliest human malignancies, as a homogeneous disease. Accordingly, SCLC therapy comprises chemoradiation with or without immunotherapy. Meanwhile, recent studies have made significant advances in subclassifying SCLC based on the elevated expression of the transcription factors ASCL1, NEUROD1, and POU2F3, as well as on certain inflammatory characteristics. The role of the transcription regulator YAP1 in defining a unique SCLC subset remains to be established. Although preclinical analyses have described numerous subtype-specific characteristics and vulnerabilities, the so far non-existing clinical subtype distinction may be a contributor to negative clinical trial outcomes. This comprehensive review aims to provide a framework for the development of novel personalized therapeutic approaches by compiling the most recent discoveries achieved by preclinical SCLC research. We highlight the challenges faced due to limited access to patient material as well as the advances accomplished by implementing state-of-the-art models and methodologies.